Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1886 1
1963 1
1967 1
1968 1
1971 1
1972 1
1973 2
1974 2
1975 12
1976 12
1977 11
1978 14
1979 16
1980 9
1981 37
1982 47
1983 39
1984 43
1985 48
1986 40
1987 56
1988 50
1989 70
1990 84
1991 82
1992 88
1993 114
1994 120
1995 130
1996 138
1997 119
1998 149
1999 155
2000 154
2001 180
2002 201
2003 219
2004 229
2005 247
2006 272
2007 277
2008 291
2009 311
2010 342
2011 368
2012 395
2013 425
2014 412
2015 463
2016 370
2017 279
2018 358
2019 368
2020 382
2021 445
2022 391
2023 309
2024 62

Text availability

Article attribute

Article type

Publication date

Search Results

8,546 results

Results by year

Filters applied: . Clear all
Page 1
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Müller-Tidow C, Dreger P. Schubert ML, et al. Among authors: schmitt m. Ann Oncol. 2021 Jan;32(1):34-48. doi: 10.1016/j.annonc.2020.10.478. Epub 2020 Oct 21. Ann Oncol. 2021. PMID: 33098993 Free article. Review.
Due to the nature of CAR T cells as living drugs, they display a unique toxicity profile. As CAR T-cell therapy is extending towards other diseases and being more broadly employed in hematology and oncology, optimal management strategies of side-effects associated w …
Due to the nature of CAR T cells as living drugs, they display a unique toxicity profile. As CAR T-cell therapy is extending t …
Role of the IL23/IL17 Pathway in Crohn's Disease.
Schmitt H, Neurath MF, Atreya R. Schmitt H, et al. Front Immunol. 2021 Mar 30;12:622934. doi: 10.3389/fimmu.2021.622934. eCollection 2021. Front Immunol. 2021. PMID: 33859636 Free PMC article. Review.
IL23 is a member of the IL12 family of cytokines and is able to enhance and affect the expansion of pathogenic T helper type 17 (Th17) cells through various mechanisms, including maintenance of Th17 signature genes, upregulation of effector genes or suppression of repressi …
IL23 is a member of the IL12 family of cytokines and is able to enhance and affect the expansion of pathogenic T helper type 17 (Th17 …
Rgs16 promotes antitumor CD8(+) T cell exhaustion.
Weisshaar N, Wu J, Ming Y, Madi A, Hotz-Wagenblatt A, Ma S, Mieg A, Hering M, Zettl F, Mohr K, Schlimbach T, Ten Bosch N, Hertel F, Müller L, Byren H, Wang M, Borgers H, Munz M, Schmitt L, van der Hoeven F, Kloz U, Carretero R, Schleußner N, Jackstadt RF, Hofmann I, Cui G. Weisshaar N, et al. Among authors: schmitt l. Sci Immunol. 2022 May 27;7(71):eabh1873. doi: 10.1126/sciimmunol.abh1873. Epub 2022 May 27. Sci Immunol. 2022. PMID: 35622904
T cells become functionally exhausted in tumors, limiting T cell-based immunotherapies. Although several transcription factors regulating the exhausted T (T(ex)) cell differentiation are known, comparatively little is known about the regulators of T …
T cells become functionally exhausted in tumors, limiting T cell-based immunotherapies. Although several transcription factors …
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity.
Sauer T, Parikh K, Sharma S, Omer B, Sedloev D, Chen Q, Angenendt L, Schliemann C, Schmitt M, Müller-Tidow C, Gottschalk S, Rooney CM. Sauer T, et al. Among authors: schmitt m. Blood. 2021 Jul 29;138(4):318-330. doi: 10.1182/blood.2020008221. Blood. 2021. PMID: 34323938 Free PMC article.
The structural composition of the CAR strongly influenced expression levels, viability, expansion, and cytotoxic capacities of CD70scFv-based CAR T cells, but CD27z-CAR T cells demonstrated superior proliferation and antitumor activity in vitro and in vivo, compared …
The structural composition of the CAR strongly influenced expression levels, viability, expansion, and cytotoxic capacities of CD70scFv-base …
Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCR.
Schanda N, Sauer T, Kunz A, Hückelhoven-Krauss A, Neuber B, Wang L, Hinkelbein M, Sedloev D, He B, Schubert ML, Müller-Tidow C, Schmitt M, Schmitt A. Schanda N, et al. Among authors: schmitt m, schmitt a. Cells. 2021 Nov 17;10(11):3208. doi: 10.3390/cells10113208. Cells. 2021. PMID: 34831430 Free PMC article.
Chimeric-antigen-receptor-T (CAR-T) cells are currently revolutionizing the field of cancer immunotherapy. ...In conclusion, quality control of CAR-T cell products can be performed by FACS and qPCR. For the monitoring of CAR-T cell frequencies by FACS …
Chimeric-antigen-receptor-T (CAR-T) cells are currently revolutionizing the field of cancer immunotherapy. ...In conclusion, q …
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.
Chapuis AG, Egan DN, Bar M, Schmitt TM, McAfee MS, Paulson KG, Voillet V, Gottardo R, Ragnarsson GB, Bleakley M, Yeung CC, Muhlhauser P, Nguyen HN, Kropp LA, Castelli L, Wagener F, Hunter D, Lindberg M, Cohen K, Seese A, McElrath MJ, Duerkopp N, Gooley TA, Greenberg PD. Chapuis AG, et al. Among authors: schmitt tm. Nat Med. 2019 Jul;25(7):1064-1072. doi: 10.1038/s41591-019-0472-9. Epub 2019 Jun 24. Nat Med. 2019. PMID: 31235963 Free PMC article.
Thus, AML relapse risk might be more effectively reduced with T cells expressing receptors (TCRs) that target selected AML antigens(6). We therefore isolated a high-affinity Wilms' Tumor Antigen 1-specific TCR (TCR(C4)) from HLA-A2(+) normal donor repertoires, inserted TCR …
Thus, AML relapse risk might be more effectively reduced with T cells expressing receptors (TCRs) that target selected AML antigens(6 …
A vaccine targeting mutant IDH1 in newly diagnosed glioma.
Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, Green E, Justesen S, Behrens GA, Breckwoldt MO, Freitag A, Rother LM, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Stevanovic S, Tabatabai G, Steinbach JP, Bendszus M, von Deimling A, Schmitt M, Wick W. Platten M, et al. Among authors: schmitt m, schmitt a. Nature. 2021 Apr;592(7854):463-468. doi: 10.1038/s41586-021-03363-z. Epub 2021 Mar 24. Nature. 2021. PMID: 33762734 Free PMC article. Clinical Trial.
An IDH1(R132H)-specific peptide vaccine (IDH1-vac) induces specific therapeutic T helper cell responses that are effective against IDH1(R132H)(+) tumours in syngeneic MHC-humanized mice(4,6-8). ...Pseudoprogression was associated with increased vaccine-induced peripheral …
An IDH1(R132H)-specific peptide vaccine (IDH1-vac) induces specific therapeutic T helper cell responses that are effective against ID …
Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease.
Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S, Hirschmann S, Hildner K, Waldner MJ, Mudter J, Hartmann A, Grützmann R, Neufert C, Münster T, Neurath MF, Atreya R. Schmitt H, et al. Gut. 2019 May;68(5):814-828. doi: 10.1136/gutjnl-2017-315671. Epub 2018 May 30. Gut. 2019. PMID: 29848778 Free PMC article.
Apoptosis-resistant TNFR2+IL23R+ T cells were significantly expanded in anti-TNF non-responders compared with responders, expressed the gut tropic integrins alpha4beta7, and exhibited increased expression of IFN-gamma, T-bet, IL-17A and RORgammat compared with TNFR2 …
Apoptosis-resistant TNFR2+IL23R+ T cells were significantly expanded in anti-TNF non-responders compared with responders, expressed t …
T(H)1 cytokines induce senescence in AML.
Hashimoto H, Güngör D, Krickeberg N, Schmitt J, Doll L, Schmidt M, Schleicher S, Criado-Moronati E, Schilbach K. Hashimoto H, et al. Among authors: schmitt j. Leuk Res. 2022 Jun;117:106842. doi: 10.1016/j.leukres.2022.106842. Epub 2022 Apr 26. Leuk Res. 2022. PMID: 35490594 Free article.
This study therefore examines senescence induction in AML cells by PRAME-specific T(H)1 cells. Analysis of cell cycle and marker expression demonstrate that the supernatants of antigen-stimulated PRAME-specific T(H)1 cells induce senescence in AML cell lines Kasumi …
This study therefore examines senescence induction in AML cells by PRAME-specific T(H)1 cells. Analysis of cell cycle and marker expr …
Cell-based immunotherapy approaches for multiple myeloma.
Kriegsmann K, Kriegsmann M, Cremer M, Schmitt M, Dreger P, Goldschmidt H, Müller-Tidow C, Hundemer M. Kriegsmann K, et al. Among authors: schmitt m. Br J Cancer. 2019 Jan;120(1):38-44. doi: 10.1038/s41416-018-0346-9. Epub 2018 Dec 6. Br J Cancer. 2019. PMID: 30518815 Free PMC article. Review.
Despite the arrival of novel therapies, multiple myeloma (MM) remains incurable and new treatment options are needed. Chimeric antigen receptor (CAR) T cells are genetically modified T cells that express a CAR directed against specific tumour antigens. CAR T …
Despite the arrival of novel therapies, multiple myeloma (MM) remains incurable and new treatment options are needed. Chimeric antigen recep …
8,546 results